Cumberland Pharmaceuticals Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Cumberland Pharmaceuticals Inc. (CPIX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$960.54 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-11-13
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $6.03M, a 156.20% increase year-over-year.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$3.66M, a 668.33% decline year-over-year.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$3.33M.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$10.32M, a 404.08% decline year-over-year.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$17.47M, a 260.27% decline from fiscal 2017.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $10.90M.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.69M.
- Cumberland Pharmaceuticals Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$1.66M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $2.37M derived: sum of 2 quarters · filed 2019-11-13 | -$960.54K 10-Q · filed 2019-11-13 | -$11.28M derived: sum of 4 quarters · filed 2019-11-13 |
| 2019-06-30 | -$3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$6.99M 10-Q · filed 2019-08-14 | -$17.31M derived: sum of 3 quarters · filed 2019-08-14 | -$14.96M derived: sum of 4 quarters · filed 2019-11-13 |
| 2019-03-31 | -$3.33M 10-Q · filed 2019-05-15 | -$13.65M derived: sum of 2 quarters · filed 2019-05-15 | -$11.30M derived: sum of 3 quarters · filed 2019-11-13 | -$10.65M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-12-31 | -$10.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$7.97M derived: sum of 2 quarters · filed 2019-11-13 | -$7.32M derived: sum of 3 quarters · filed 2019-11-13 | -$17.47M 10-K · filed 2019-03-12 |
| 2018-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $3.00M derived: sum of 2 quarters · filed 2019-11-13 | -$7.15M 10-Q · filed 2019-11-13 | -$3.76M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $643.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$9.51M 10-Q · filed 2019-08-14 | -$6.11M derived: sum of 3 quarters · filed 2019-08-14 | $1.29M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$10.15M 10-Q · filed 2019-05-15 | -$6.76M derived: sum of 2 quarters · filed 2019-05-15 | $646.87K derived: sum of 3 quarters · filed 2019-05-15 | $288.73K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $10.80M derived: sum of 2 quarters · filed 2019-03-12 | $10.44M derived: sum of 3 quarters · filed 2019-03-12 | $10.90M 10-K · filed 2019-03-12 |
| 2017-09-30 | $7.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $7.04M derived: sum of 2 quarters · filed 2018-11-14 | $7.51M 10-Q · filed 2018-11-14 | $6.47M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$358.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $105.78K 10-Q · filed 2018-08-14 | -$930.14K derived: sum of 3 quarters · filed 2019-03-12 | -$1.22M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $463.91K 10-Q · filed 2018-05-09 | -$572.00K derived: sum of 2 quarters · filed 2019-03-12 | -$863.00K derived: sum of 3 quarters · filed 2019-03-12 | -$1.47M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$1.33M derived: sum of 2 quarters · filed 2019-03-12 | -$1.93M derived: sum of 3 quarters · filed 2019-03-12 | -$3.69M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$291.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$894.53K derived: sum of 2 quarters · filed 2017-11-08 | -$2.66M 10-Q · filed 2017-11-08 | -$2.77M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | -$603.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$2.37M 10-Q · filed 2017-08-09 | -$2.48M derived: sum of 3 quarters · filed 2018-03-09 | -$3.10M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | -$1.76M 10-Q · filed 2017-05-15 | -$1.88M derived: sum of 2 quarters · filed 2018-03-09 | -$2.50M derived: sum of 3 quarters · filed 2018-03-09 | -$2.60M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | -$113.23K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$737.62K derived: sum of 2 quarters · filed 2018-03-09 | -$841.69K derived: sum of 3 quarters · filed 2018-03-09 | -$1.66M 10-K · filed 2018-03-09 |
| 2015-09-30 | -$624.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$728.46K derived: sum of 2 quarters · filed 2016-11-03 | -$1.55M 10-Q · filed 2016-11-03 | -$1.33M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | -$104.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$925.36K 10-Q · filed 2016-08-05 | -$703.40K derived: sum of 3 quarters · filed 2017-03-13 | -$110.16K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | -$821.29K 10-Q · filed 2016-05-13 | -$599.33K derived: sum of 2 quarters · filed 2017-03-13 | -$6.09K derived: sum of 3 quarters · filed 2017-03-13 | -$3.21K derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | $221.96K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $815.20K derived: sum of 2 quarters · filed 2017-03-13 | $818.08K derived: sum of 3 quarters · filed 2017-03-13 | -$1.00M 10-K · filed 2017-03-13 |
| 2014-09-30 | $593.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $596.12K derived: sum of 2 quarters · filed 2015-11-06 | -$1.23M 10-Q · filed 2015-11-06 | -$6.37M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $2.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$1.82M 10-Q · filed 2015-08-07 | -$6.96M derived: sum of 3 quarters · filed 2016-03-14 | -$10.61M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | -$1.82M 10-Q · filed 2015-05-15 | -$6.96M derived: sum of 2 quarters · filed 2016-03-14 | -$10.62M derived: sum of 3 quarters · filed 2016-03-14 | -$12.16M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | -$5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$8.80M derived: sum of 2 quarters · filed 2016-03-14 | -$10.34M derived: sum of 3 quarters · filed 2016-03-14 | -$13.48M 10-K · filed 2016-03-14 |
| 2013-09-30 | -$3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$5.20M derived: sum of 2 quarters · filed 2014-11-07 | -$8.34M 10-Q · filed 2014-11-07 | -$4.79M derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$4.68M 10-Q · filed 2014-08-08 | -$1.14M derived: sum of 3 quarters · filed 2015-03-09 | -$2.61M derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-03-31 | -$3.14M 10-Q · filed 2014-05-12 | $407.97K derived: sum of 2 quarters · filed 2015-03-09 | -$1.06M derived: sum of 3 quarters · filed 2015-03-09 | -$4.43M derived: sum of 4 quarters · filed 2015-03-09 |
| 2012-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $2.08M derived: sum of 2 quarters · filed 2015-03-09 | -$1.29M derived: sum of 3 quarters · filed 2015-03-09 | -$16.25M 10-K · filed 2015-03-09 |
| 2012-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -$4.84M derived: sum of 2 quarters · filed 2013-11-06 | -$19.80M 10-Q · filed 2013-11-06 | -$20.27M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-06-30 | -$3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$18.33M 10-Q · filed 2013-08-09 | -$18.80M derived: sum of 3 quarters · filed 2014-03-11 | -$17.56M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-03-31 | -$14.96M 10-Q · filed 2013-05-08 | -$15.43M derived: sum of 2 quarters · filed 2014-03-11 | -$14.19M derived: sum of 3 quarters · filed 2014-03-11 | -$10.32M derived: sum of 4 quarters · filed 2014-03-11 |
| 2011-12-31 | -$475.66K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $767.12K derived: sum of 2 quarters · filed 2014-03-11 | $4.64M derived: sum of 3 quarters · filed 2014-03-11 | $4.71M 10-K · filed 2014-03-11 |
| 2011-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $5.12M derived: sum of 2 quarters · filed 2012-11-02 | $5.18M 10-Q · filed 2012-11-02 | $5.56M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $3.94M 10-Q · filed 2012-08-09 | $4.31M derived: sum of 3 quarters · filed 2013-03-12 | -$1.66M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $64.87K 10-Q · filed 2012-05-04 | $440.50K derived: sum of 2 quarters · filed 2013-03-12 | -$5.54M derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | $375.63K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$5.60M derived: sum of 2 quarters · filed 2013-03-12 | -$12.81M 10-K · filed 2013-03-12 | |
| 2010-09-30 | -$5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$13.18M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$7.21M 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | $66.87M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |